Assessment of myocardial fibrosis with T1 mapping MRI

Clinical Radiology

Volumn 71, Issue 8, 2016, Pages 768-778

  Everett, R J ^a   Stirrat, C G ^a   Semple, S I R ^a,b   Newby, D E ^a,b   Dweck, M R ^a   Mirsadraee, S ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ELASTIN; GADOLINIUM;

AMYLOIDOSIS; AORTA STENOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; DISEASE COURSE; EXTRACELLULAR SPACE; FABRY DISEASE; FUNCTIONAL DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HISTOLOGY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MAGNETIC FIELD; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; VOLUME OF DISTRIBUTION; CARDIAC MUSCLE; CARDIOMYOPATHY; DIAGNOSTIC IMAGING; FIBROSIS; HEART; IMAGE ENHANCEMENT; PATHOLOGY; PROCEDURES;

CARDIOMYOPATHIES; FIBROSIS; HEART; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MYOCARDIUM;

EID: 84962561622     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2016.02.013     Document Type: Review

References (84)

1. 1 Azevedo, C.F., Nigri, M., Higuchi, M.L., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56:4 (2010), 278–287.
2. 2 Basso, C., Thiene, G., Corrado, D., et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31:8 (2000), 988–998.
3. 3 Shirani, J., Pick, R., Roberts, W.C., et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35:1 (2000), 36–44.
4. 4 Yilmaz, A., Kindermann, I., Kindermann, M., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122:9 (2010), 900–909.
5. 5 Wu, E., Ortiz, J.T., Tejedor, P., et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 94:6 (2008), 730–736.
6. 6 Kelle, S., Roes, S.D., Klein, C., et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 54:19 (2009), 1770–1777.
7. 7 Roes, S.D., Kelle, S., Kaandorp, T.A.M., et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 100:6 (2007), 930–936.
8. 8 Eitel, I., de Waha, S., Wöhrle, J., et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 64:12 (2014), 1217–1226.
9. 9 Leyva, F., Taylor, R.J., Foley, P.W.X., et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 60:17 (2012), 1659–1667.
10. 10 Bruder, O., Wagner, A., Jensen, C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:11 (2010), 875–887.
11. 11 O'Hanlon, R., Grasso, A., Roughton, M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:11 (2010), 867–874.
12. 12 Dweck, M.R., Joshi, S., Murigu, T., et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58:12 (2011), 1271–1279.
13. 13 Barone-Rochette, G., Piérard, S., de Meester de Ravenstein, C., et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol 64:2 (2014), 144–154.
14. 14 Kim, R.J., Fieno, D.S., Parrish, T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100:19 (1999), 1992–2002.
15. 15 Wu, E., Judd, R.M., Vargas, J.D., et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357:9249 (2001), 21–28.
16. 16 Kellman, P., Arai, A.E., McVeigh, E.R., et al. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 47:2 (2002), 372–383.
17. 17 Messroghli, D.R., Walters, K., Plein, S., et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med 58:1 (2007), 34–40.
18. 18 van Kranenburg, M., Magro, M., Thiele, H., et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging 7:9 (2014), 930–939.
19. 19 Flett, A.S., Hasleton, J., Cook, C., et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 4:2 (2011), 150–156.
20. 20 Khawaja, A.Z., Cassidy, D.B., Shakarchi Al, J., et al. Revisiting the risks of MRI with gadolinium based contrast agents-review of literature and guidelines. Insights Imaging 6:5 (2015), 553–558.
21. 21 Moon, J.C., Messroghli, D.R., Kellman, P., et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiov Magn Reson, 15(1), 2013, 92.
22. 22 Look, D.C., Locker, D.R., Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 41:2 (1970), 250–251.
23. 23 Messroghli, D.R., Radjenovic, A., Kozerke, S., et al. Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 52:1 (2004), 141–146.
24. 24 Piechnik, S.K., Ferreira, V.M., Dall'Armellina, E., et al. Shortened modified Look-Locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiov Magn Reson, 12(1), 2010, 69.
25. 25 Kellman, P., Hansen, M.S., T1-mapping in the heart: accuracy and precision. J Cardiov Magn Reson, 16(1), 2014, 2.
26. 26 Dass, S., Suttie, J.J., Piechnik, S.K., et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 5:6 (2012), 726–733.
27. 27 Chow, K., Flewitt, J.A., Green, J.D., et al. Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med 71:6 (2014), 2082–2095.
28. 28 Kellman, P., Wilson, J.R., Xue, H., et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiov Magn Reson, 14(1), 2012, 63.
29. 29 Flett, A.S., Hayward, M.P., Ashworth, M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122:2 (2010), 138–144.
30. 30 White, S.K., Sado, D.M., Fontana, M., et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 6:9 (2013), 955–962.
31. 31 Miller, C.A., Naish, J.H., Bishop, P., et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 6:3 (2013), 373–383.
32. 32 Piechnik, S.K., Ferreira, V.M., Lewandowski, A.J., et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiov Magn Reson, 15(1), 2013, 13.
33. 33 Dabir, D., Child, N., Kalra, A., et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiov Magn Reson, 16(1), 2014, 69.
34. 34 de Jong, S., van Veen, T.A.B., de Bakker, J.M.T., et al. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol 57:5 (2011), 522–535.
35. 35 Lee, S.-P., Lee, W., Lee, J.M., et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology 274:2 (2015), 359–369.
36. 36 Bull, S., White, S.K., Piechnik, S.K., et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 99:13 (2013), 932–937.
37. 37 Chin, C.W.L., Semple, S., Malley, T., et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovas Imaging 15:5 (2014), 556–565.
38. 38 Iles, L., Pfluger, H., Phrommintikul, A., et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52:19 (2008), 1574–1580.
39. 39 Sibley, C.T., Noureldin, R.A., Gai, N., et al. T1 Mapping in cardiomyopathy at cardiac mr: comparison with endomyocardial biopsy. Radiology 265:3 (2012), 724–732.
40. 40 Mascherbauer, J., Marzluf, B.A., Tufaro, C., et al. Cardiac magnetic resonance post-contrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 6:6 (2013), 1056–1065.
41. 41 Fontana, M., White, S.K., Banypersad, S.M., Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification. J Cardiov Magn Reson, 14, 2012, 88.
42. 42 Kim, R.J., Wu, E., Rafael, A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:20 (2000), 1445–1453.
43. 43 Pegg, T.J., Selvanayagam, J.B., Jennifer, J., Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium. J Cardiov Magn Reson, 12, 2010, 56.
44. 44 Kali, A., Choi, E.-Y., Sharif, B., et al. Native T1 mapping by 3-T CMR imaging for characterization of chronic myocardial infarctions. JACC Cardiovasc Imaging 8:9 (2015), 1019–1030.
45. 45 Ugander, M., Oki, A.J., Hsu, L.-Y., et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 33:10 (2012), 1268–1278.
46. 46 Mann, D.L., Mechanisms and models in heart failure: a combinatorial approach. Circulation 100:9 (1999), 999–1008.
47. 47 Heling, A., Zimmermann, R., Kostin, S., et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 86:8 (2000), 846–853.
48. 48 Assomull, R.G., Prasad, S.K., Lyne, J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48:10 (2006), 1977–1985.
49. 49 Tachi, M., Amano, Y., Inui, K., et al. Relationship of postcontrast myocardial T1 value and delayed enhancement to reduced cardiac function and serious arrhythmia in dilated cardiomyopathy with left ventricular ejection fraction less than 35. Acta Radiol, 2015.
50. 50 Han, Y., Peters, D.C., Dokhan, B., et al. Shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy. J Magn Reson Imaging 30:5 (2009), 967–972.
51. 51 Hayashida, T., Sueyoshi, E., Nagayama, H., et al. Comparison study on different quantification methods of diffuse myocardial fibrosis of dilated cardiomyopathy using myocardial T1 value. Open J Radiol 03:03 (2013), 117–123.
52. 52 Su, M.-Y.M., Lin, L.-Y., Tseng, Y.-H.E., et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 7:10 (2014), 991–997.
53. 53 Wong, T.C., Piehler, K., Meier, C.G., et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short term mortality. Circulation 126:10 (2012), 1206–1216.
54. 54 Wong, T.C., Piehler, K.M., Kang, I.A., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35:10 (2014), 657–664.
55. 55 Hogg, K., Swedberg, K., McMurray, J., Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:3 (2004), 317–327.
56. 56 Bhatia, R.S., Tu, J.V., Lee, D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:3 (2006), 260–269.
57. 57 Kato, S., Saito, N., Kirigaya, H., et al. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 191 (2015), 314–319.
58. 58 Hein, S., Arnon, E., Kostin, S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107:7 (2003), 984–991.
59. 59 Dweck, M.R., Boon, N.A., Newby, D.E., Calcific aortic stenosis. J Am Coll Cardiol 60:19 (2012), 1854–1863.
60. 60 Ross, J., Braunwald, E., Aortic stenosis. Circulation 38:Suppl. (1968), 61–67.
61. 61 Connolly, H.M., Oh, J.K., Orszulak, T.A., et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation 95:10 (1997), 2395–2400.
62. 62 Krayenbuehl, H.P., Hess, O.M., Monrad, E.S., et al. Left-ventricular myocardial structure in aortic-valve disease before, intermediate, and late after aortic-valve replacement. Circulation 79:4 (1989), 744–755.
63. 63 Debl, K., Djavidani, B., Buchner, S., et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92:10 (2006), 1447–1451.
64. 64 Chin, C.W.L., Shah, A.S.V., McAllister, D.A., et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 35:34 (2014), 2312–2321.
65. 65 Flett, A.S., Sado, D.M., Quarta, G., et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging, 13(10), 2012 jes102–826.
66. 66 Querejeta, R., López, B., González, A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:10 (2004), 1263–1268.
67. 67 Díez, J., Querejeta, R., López, B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:21 (2002), 2512–2517.
68. 68 Coelho-Filho, O.R., Mongeon, F.-P., Mitchell, R., et al. Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging 6:1 (2013), 134–141.
69. 69 Kuruvilla, S., Janardhanan, R., Antkowiak, P., et al. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging 8:2 (2015), 172–180.
70. 70 Moon, J.C.C., Reed, E., Sheppard, M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:12 (2004), 2260–2264.
71. 71 Adabag, A.S., Maron, B.J., Appelbaum, E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:14 (2008), 1369–1374.
72. 72 Ellims, A.H., Iles, L.M., Ling, L.-H., et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging 15:10 (2014), 1108–1116.
73. 73 Kellman, P., Wilson, J.R., Xue, H., Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn, 14, 2012, 64.
74. 74 Puntmann, V.O., Voigt, T., Chen, Z., et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6:4 (2013), 475–484.
75. 75 Sado, D.M., Flett, A.S., Banypersad, S.M., et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98:19 (2012), 1436–1441.
76. 76 Brouwer, W.P., Baars, E.N., Germans, T., et al. In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiov Magn Reson, 16(1), 2014, 28.
77. 77 Małek, Ł.A., Werys, K., Kłopotowski, M., et al. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy — comparison with late enhancement quantification. Magn Reson Imaging 33:6 (2015), 718–724.
78. 78 Sado, D.M., White, S.K., Piechnik, S.K., et al. Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:3 (2013), 392–398.
79. 79 Karamitsos, T.D., Piechnik, S.K., Banypersad, S.M., et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6:4 (2013), 488–497.
80. 80 Sado, D.M., Maestrini, V., Piechnik, S.K., et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Im 41:6 (2015), 1505–1511.
81. 81 Ferreira, V.M., Piechnik, S.K., Dall'Armellina, E., et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiov Magn Reson, 14(1), 2012, 42.
82. 82 Treibel, T.A., Fontana, M., Maestrini, V., et al. Synthetic ECV — simplifying ECV quantification by deriving haematocrit from T1 blood. Heart 101:Suppl. 2 (2015), A16–A17.
83. 83 Helm, P.A., Caravan, P., French, B.A., et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 247:3 (2008), 788–796.
84. 84 Wildgruber, M., Bielicki, I., Aichler, M., et al. Assessment of myocardial infarction and postinfarction scar remodeling with an elastin-specific magnetic resonance agent. Circ Cardiovasc Imaging 7:2 (2014), 321–329.